ACHAOGEN

Achaogen Investor Relations Department 7000 Shoreline Court, 3rd Floor South San Francisco, CA 94080 United States

Visit IR website ☐ Sign-up for email alerts ☐ ☐

Trade Time: 4:00 PM ET Jun 22, 2018 Change: -0.03 ♣ (0.241% Day Range 12.00 - 12.67 52-Week Range 9.83 - 25.22	NASDAQ: AKAO	
Jun 22, 2018 Change: -0.03 ♣ (0.241% Day Range 12.00 - 12.67 52-Week Range 9.83 - 25.22	Last Trade:	12.42
Day Range 12.00 - 12.67 52-Week Range 9.83 - 25.22	Trade Time:	4:00 PM ET Jun 22, 2018
52-Week Range 9.83 - 25.22	Change:	-0.03 🖶 (0.241%)
g	Day Range	12.00 - 12.67
Volume 1,495,194	52-Week Range	9.83 - 25.22
	Volume	1,495,194

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments against multidrug resistant (MDR), gram-negative infections. We are developing plazomicin, our lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infections (cUTI), bloodstream infections and other infections due to MDR Enterobacteriaceae, including carbapenemresistant Enterobacteriaceae (CRE). In 2013, the Centers for Disease Control and Prevention identified CRE... (more)

Stock Performance



Press Releases [View all]

Jun 11, 2018

Achaogen Highlights Multiple Plazomicin
Presentations at ASM Microbe 2018 Annual
Meeting

May 24, 2018

Achaogen Announces Multiple Plazomicin
Presentations at ASM Microbe 2018 Annual
Meeting

May 4, 2018

Achaogen Reports First Quarter 2018
Financial Results and Provides Corporate
Update

May 2, 2018

Achaogen Announces FDA Advisory
Committee Voted Unanimously in Favor of
Plazomicin for Treatment of Adults with
Complicated Urinary Tract Infections

May 2, 2018

Achaogen Stock Trading Halted Today

Financials [View all]

First Quarter Financial Results

Feb 27, 2018

Annual Report (10-K)

Apr 18, 2018

Proxy Statement (DEF 14A)

May 7, 2018

Quarterly Report (10-Q)

Nov 8, 2017

Quarterly Report (10-Q)

Aug 8, 2017

Quarterly Report (10-Q)